Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With<i>EGFR</i>-Mutated Advanced Non–Small Cell Lung CancerPedro Nazareth Aguiar(Sociedade Brasileira de Oncologia Clínica), Gilberto Lopes(University of Miami)JAMA OncologyMay 31, 201810.1001/jamaoncol.2018.1395Cited by 121SaveCiteExport RISWatch citationsRelated PapersPembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial|The Lancet|2019|3.3kClinical impact of COVID-19 on patients with cancer (CCC19): a cohort study|The Lancet|2020|1.8kUtilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study|Cancer Discovery|2020|138Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry|Blood|2020|8